Composition for body fat reduction

FIELD: medicine.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to preparation of a composition for body fat reduction. A group of inventions is offered: the composition for body fat reduction, containing astaxanthin as an effective ingredient in amount 0.001-99.9% of total weight; the composition for body fat reduction which is prepared by grinding Haematococcus alga and extraction of ground Haematococcus alga in a solvent in which Haematococcus alga extract containing astaxanthin is found in amount 0.001-99.9% of total weight; an agent for body fat reduction which contains any of compositions; food and beverage for body fat reduction which contain any of compositions and the method of body fat reduction which involves the introduction or intake by an individual of any composition in amount 0.2-100.0 mg a day at free astaxanthin.

EFFECT: body fat reduction without weight variations.

12 cl, 4 ex, 2 tbl

 

The present invention relates to compositions for reducing body fat, which contains astaxanthin as an effective ingredient, and relates to compositions for reducing body fat, which can be obtained by grinding the algae Haetmatococcus and extraction of algae Haetmatococcus organic solvent. These compositions take as a drug or food or drink, resulting in the present invention refers to medicines and food, which are effective to reduce the amount of fat in the body and for the prevention, improvement and treatment of obesity and related diseases.

The level of technology

In recent years, diseases associated with lifestyle has increased due to the consumption of energy-dense foods, lifestyle changes, lack of exercise, stress, etc. is becoming a serious social problem. Especially obesity or excess body weight, which is measured as the quantity of fat in the body, are a major problem for more than 20 percent of all Japanese. Obesity means a condition of the body in which energy consumption is becoming more redundant than the consumption, and the accumulation of adipose tissue occurs in Bo who Isham number, than normal. In the case of the Japanese revealed that adult men have more than 25 percent of the excess fat in the body, while adult women are more than 30 percent of excess body fat. When a person becomes fat, adipose tissue accumulates in large quantities, resulting in a number of diseases, such as hypertension, cardiovascular disease, hyperlipidemia, arteriosclerosis, diabetes, etc. occur and cause complications, such as damage to blood vessels, blurred vision, nerve damage, lower resistance, etc.

There have been many studies to solve the problems of obesity, which is the main cause of diseases associated with lifestyle and designed and carried out various methods of treatment, such as treatment with diet, exercise, medical treatment etc

Although treatment with diet and exercise in General are methods of treating obesity, prolonged use of low-calorie diet and exercise, requiring time and place to conduct adequate physical exercise are practically difficult in the modern society due to the increase in energy consumption of the diet and changes in the working environment.

As a medical treatment is obesity provide a way to improve the energy consumption by accelerating the breakdown of fat in adipose tissue and method of inhibiting energy consumption by reducing the receipt of lipids, saccharides, etc. by their absorption from the digestive canal or restrictions of use. However, medical treatment has some problems, but it may not be easy-to-do for the following reasons.

Adequate dosage; side effects, which are expressed in the fact that excessive absorption prevents the absorption of essential nutrients, loss of balance absorbable nutrients and requires a doctor's prescription.

Found the composition to reduce the fat content in the body, which is obtained from natural materials, which has no side effects and which can easily be used as food. Known means for reducing the fat content in the body is contained in Garcinia cambogia and citrus (Patent source 1), the method of the conjugated linoleic acid (Source of patent literature 2) and method of reception of vitamin D3(Source of patent literature 3).

Astaxanthin is a carotenoid, such as β-carotene, and red pigment, which is widely distributed in natural sources, especially in the ocean in the shell of shrimp, crabs and so on; in fish, such as salmon, sea bass, etc. in algae such as green algae Haetmatococcus etc., yeast, such as red yeastPhaffiaand d, and which was widely used as food. It is known to possess antioxidant properties, approximately 1000 times stronger than vitamin E, and about 40 times stronger than β-carotene.

Other functional characteristics of astaxanthin, are anti-inflammatory, antiarteriosclerotic action, antidiabetic action, a protective effect on the retina against light damage, action, normalizing circadian rhythm, immunopotency action, anti-stress action, action, improves sperm quality, action, preventing the development of induced bladder cancer, etc. are Also reported action aimed at physical exercise, the effect of increasing the duration of muscular work (Source of patent literature 4), and the effect of inhibiting the growth of lactic acid in the blood during exercise (Source of non-patent literature 1), rehabilitation the effect on fatigue after exercise (Source of non-patent literature 2).

However, it was reported that astaxanthin extract from algae Haetmatococcus, which was obtained by grinding algae Haetmatococcus and extraction of crushed seaweed Haetmatococcus solvent has an effect on reducing fat content in the body is measured and prevents the increase in the amount of fat in the body and, therefore, they have therapeutic and preventive effects on obesity.

[Patent source 1] JP2001-321126 A

[Patent source 2] JP10-508189 A

[Patent reference 3] JP3-3210156 A

[Patent source 4] JP2001-514215 A

[Non-patent source 1]: Clinical medicine; 18(9), 85-1100, 2002.

[Non-patent source 2]: Science of fatigue and rest; 18(1), 35-46, 2003.

The purpose of the present invention is to provide a composition having effects on the reduction of fat content in the body and preventing the increase of body fat and, therefore, directed to treatment, improvement and prevention of various kinds of diseases caused by obesity, which is manifested by increased body fat, and the emergence and maintenance of good shape due to the effect of weight loss.

Means of solving the problem of the invention

As a result of careful studies to achieve the above objective, the creators of the present invention have found that astaxanthin and extract algae Haetmatococcus, which was obtained by grinding algae Haetmatococcus and extraction of crushed seaweed Haetmatococcus solvent, showed the effects of reducing fat in the body and prevent the accumulation of fat in the body and have completed the present invention.

The present invention represents:

(1) composers who, s to reduce the amount of fat in the body, which contains astaxanthin as an effective ingredient,

(2) a composition for reducing the amount of fat in the body, which is obtained by grinding algae Haetmatococcus and extraction of crushed seaweed Haetmatococcus solvent

(3) a composition for reducing the amount of fat in the body, which contains the inclusion of one or more active ingredients of the adsorbent and solvent in any of the songs(1)-(2),

(4) means for reducing the amount of fat in the body, containing any of the compositions(1)-(3),

(5) food and drink to reduce the amount of fat in the body that contain any of the compositions(1)-(3),

(6) a method of reducing the amount of fat in the body, which includes the introduction or admission of any of the compositions (1)to(3) person.

The best way of carrying out the invention

Composition for reducing body fat, which contains astaxanthin as an effective ingredient, as well as a composition for reducing the amount of fat in the body, which is obtained by grinding algae Haetmatococcus and extraction of crushed seaweed Haetmatococcus solvent, is injected or taken as a medicine or food and drink, whereby the fat content in the body can be reduced and the increase can be prevented without any with the accompanying side effects and can be treated to improve the condition and prevent disease, the cause of which is the excess amount of body fat or obesity.

The term "astaxanthin" which means that he isolated from natural sources or obtained by synthesis. As isolated from a natural source it may be derived from the shells, eggs and tubular bodies, such as shrimp, krill, crabs and the like; skin and eggs of various fish and shellfish; algae such as green algae Haetmatococcus etc., yeast, such as red yeastPhaffiaetc., oceanic bacteria and plant seeds, such asAdonis amurensisandRanunculus acris. Extract from natural sources or chemically synthesized product went on sale, and since they are readily available.

Astaxanthin can be obtained through the cultivation of red yeastPhaffia,algae Haetmatococcus, oceanic bacteria, etc. in an appropriate environment in accordance with the known method. Green algae Haetmatococcus is preferred from the viewpoint of ease of cultivation and extraction, the content of astaxanthin in the highest concentrations and high productivity.

Algae Haetmatococcus is a green algae, belonging to the families Volvocida, Chlamydomonadacea. As it is usual green algae, it has a high content is their chlorophyll and green and swims with two flagella. But it forms a dormant spores under adverse conditions, such as lack of source of nutrients, temperature changes and other, which results in a high content of astaxanthin and red and spherical form. Although Haetmatococcus in another state may be used in the present invention, it is preferable to use Haetmatococcus forming dormant spores, due to the high content of astaxanthin.

Can be taken green algae belonging to the genus Haetmatococcus, it isHaetmatococcus pluvialis, Haetmatococcus lacustris, Haetmatococcus capensis, Haetmatococcus droebakensisandHaetmatococcus zimbabwiensis.Among themHaetmatococcus pluvialisis the most preferred.

As a method of culturing algae Haetmatococcus method of culturing algae Haetmatococcus using the device for culturing sealed type is preferred because there is no possibility of mixing and reproduction of various species of microorganisms and because exposure to a mixture of other contaminants is very low. For example, suitable are the method of cultivation with the use of the device for culturing sealed type vodopodobnogo, conical or cylindrical shape, in which the culture incubators equipped with optional mobile gas ejector(WO 99/50384), the method of cultivation in which the light source is in the tank for culturing and cultivation is carried out under irradiation of light from the inner part of the vessel for culturing, the method of cultivation with the use of the vessel for culturing cylindrical, flat or tubular form and the manner in which the cultivation is carried out under irradiation of light having a peak wavelength below approximately 540 nm (JP2004-A).

As a method of obtaining the extract from algae Haetmatococcus containing astaxanthin included in the present invention, taken (1) a method in which after drying and grinding Haetmatococcus spend supercritical extraction with carbon dioxide as a solvent for extraction and carbon dioxide is removed by obtaining the extract (method supercritical extraction), and (2) a method in which the algae Haetmatococcus pulverized and subjected to extraction with a solvent and the solvent is removed from the extract (grinding method extraction).

The way supercritical extraction specifically illustrated below.

After the algae Haetmatococcus was dried and crushed, shredded seaweed Haetmatococcus laid in a layer of extraction, the extraction is carried out with carbon dioxide in supercritical state as the extractant and then carbon dioxide from Aleut with obtaining the extract. Despite the fact that the substance in the supercritical extraction has the ability like a liquid, it has the ability to diffusion approximately as the gas, and therefore, it has high extraction efficiency so that the extractant, which is the extraction solvent, can be easily and completely removed without leaving residue. Supercritical extraction can be carried out by a method described in JP 2004-41147 A.

As conditions for supercritical extraction in the case where the extractant used carbon dioxide, the temperature is usually 31-80°C, preferably 31-50°C, the pressure is 7,38-40 MPa, preferably 10-38 MPa. In this case, the carbon dioxide supercritical fluid is not limited to the fluid in the supercritical state, namely in a state where the temperature and pressure exceed the supercritical temperature and supercritical pressure. This includes liquid medium, temperature and pressure which are close to the corresponding critical points, the so-called liquid medium in the sub-supercritical state.

To improve the extraction capacity of the auxiliary solvent is added to the supercritical fluid of carbon dioxide, thus extracting the ability can be enhanced. Examples of the support the tion of the solvent include glycerin, ethanol, water and the like, and the glycerin is preferred. The amount of auxiliary solvent increases and decreases depending on the rate of extraction. For example, when the extraction time is extended, the speed of extraction is reduced, it is therefore recommended adding auxiliary solvent to the supercritical fluid in large quantities.

As Haetmatococcus, which can be used in extraction, you can apply Haetmatococcus, crushed and dried in accordance with the generally accepted method.

Grinding and drying can be carried out in accordance with the method described in WO 2002/077105 through which the powdered form can be obtained. The powdered form can be used for filling as such. Alternatively, it may be pre-formed into pills, spherical or other shape, and the shape can be filled. To powder form and/or other form in advance is added to the above-described auxiliary solvent or synergistic extractant, thereby extracting the ability can be improved.

Enhance the extraction means are oils and fats, which are found in algae, such as Haetmatococcus or similar. By pre-adding similar substances is activated by the creation of the porosity in the form and area of contact with the supercritical fluid becomes more therefore, consider that the extraction ability increases. As oils or fats are preferred one or more selected from triglycerides of medium chain fatty acids having from 8 to 12 carbon atoms, rapeseed oil, corn oil, olive oil and the like, and triglycerides of medium chain fatty acids having from 8 to 12 carbon atoms.

The grinding method extraction is graphically illustrated below.

The grinding method extraction is a method where algae Haetmatococcus crushed, the internal substance is extracted using an organic solvent and the organic solvent is removed from the resulting extract. Grinding algae Haetmatococcus is carried out in water or an organic solvent. In the case where the seaweed Haetmatococcus was crushed in water, used for drying spray drying or the like After removal of water, the residue is subjected to extraction using an organic solvent. Especially the following method is appropriate: after the suspension of algae Haetmatococcus in an organic solvent, the suspension is passed through the grinding apparatus to effect extraction together with grinding. The solid is removed and then the organic solvent is removed to obtain the extract. This method has the characteristics of eroticheskie signs, which, since algae Haetmatococcus not apply excessive heat and algae Haetmatococcus not exposed to air during the extraction step, the oxidation of the extracted internal substances, such as lipids, astaxanthin and the like, and warned that the impurities while receiving very little. For example, using the previously stated by the present applicant (Patent Application of Japan No. 2004-253525).

Algae Haetmatococcus for use in this document can be used fresh or dried. Surfactants and antioxidants are added as needed. Examples of surfactants include polyglyceryl esters of fatty acids, glycerol esters of fatty acids, fatty acid esters of sucrose, fatty acid esters sorbitan and fatty acid esters of propylene glycol. Examples of antioxidants include vitamin E (tocopherol), derivatives of vitamin E, tocotrienol, rosemary extract, vitamin C, vitamin C derivatives, glutathione, phytic acid, flavonoids, β-carotene, etc.

Examples of organic solvents that can be used for extraction, are alcohols, such as ethanol, methanol and the like, acetone, simple ether, hexane, benzene, chloroform, methylene chloride, preferably ethanol, methanol, acetone and hexane, more prefer is Ino acetone, ethanol and hexane.

As the grinding method of the natural sources that contain carotenoids, in the present invention the natural sources that contain carotenoids, are suspended in an organic solvent, and the slurry may be subjected to grinding wet grinding apparatus, which allows the use of an organic solvent, for example a high-pressure homogenizer, an ultrasonic razmelchitel, ball mill, etc. is Preferable to carry out wet grinding in a ball mill.

As conditions of grinding in a ball mill recommended for wet grinding for a short time to prevent deterioration of the extract. The delay time is 1-30 minutes, and the peripheral speed is 2-30 m/s. The diameter of the used balls of 0.2 to 5 mm and the temperature at which is grinding 10-50°C.

Removing solids can be done the conventional way, for example by filtration under pressure, filtration under reduced pressure, spontaneous filtration and others.

The method of solvent removal can be carried out according to the standard method. The organic solvent can be removed from the filtrate by application of vacuum concentration system. To reduce the damage of the Denia extract is recommended to avoid excessive heating. It is held at 0-200°C., preferably 20-80°C and it is better to expose the loading of heat in a short time.

The solvent is removed in such quantity that it could be exposed for 0.5-20 hours, preferably 0.5 to 10 hours. Removal of the solvent in the greatest possible number concentration of the solvent can be further reduced by molecular distillation device type centrifuge evaporator with a thin membrane or the like

As astaxanthin can be used to extract algae Haetmatococcus containing astaxanthin, which was obtained by the above method, a powder or an aqueous solution containing it, the dried product and the crushed product red yeastPhaffiagreen algae Haetmatococcus or oceanic bacteria. Among them extract algae Haetmatococcus preferable, from the viewpoint of the ease of obtaining and high content of astaxanthin.

Astaxanthin is a 3,3'-dihydroxy-β,β-carotene-4,4'-dione and has the stereoisomers. Especially famous is the three stereoisomer as (3R, 3'R)-astaxanthin, (3R,3'S)-astaxanthin and (3S,3'S)-astaxanthin. Each of them can be used in the present invention.

It is known that astaxanthin can't see any variability, highly stable in mixtures and widely primestats is as food additives (Takahashi et al; Toxicological study of algae Haetmatococcus, astaxanthin - Ames research study on rats of a single toxic dose study in rats, repeated oral administration of toxic doses within 90 days - a Journal of Clinical Therapeutic and Medicine 20:86).

If this description is not specified otherwise, includes astaxanthin astaxanthin and/or its ester. In addition, ester of astaxanthin includes monoether and/or fluids.

As of astaxanthin in the composition to reduce the amount of fat in the body in the present invention can be used at least one free-form monoamines and devernay forms of astaxanthin.

Diperna form chemically and physically more stable than the free form or monoamina form, and harder subjected to oxidative decomposition, because two of its hydroxyl group protected by ester bonds. Thus, when she gets into a living organism, it undergoes rapid hydrolysis with the formation of free astaxanthin through bio causing this effect.

As monoether astaxanthin can be taken monetary obtained by esterification with a lower or higher degree of saturated fatty acids or a greater or lesser degree of unsaturated fatty acids. Specific examples of smaller and and more saturated fatty acids or a greater or lesser degree of unsaturated fatty acids include acetic acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, palmitoleic acid, heptadecanoic acid, elaidic acid, ricinoleic acid, petroselinic acid, vaccinology acid, eleostearic acid, peniteniary acid, lebanonmou acid, paineful acid, gadolinium acid, 5-Aksenovo acid, 5-docosanol acid, carolinabuy acid, Arsenieva acid, 5,13-dokozagexaenovu acid, selfrenewal acid, dezenove acid, Strangeway acid, dodecanoyl acid, oleic acid, stearic acid, eykozapentaenovuyu acid, docosahexaenoic acid, linoleic acid, linolenic acid, arachidonic acid, etc.

As diapir astaxanthin can be taken diesters obtained by etherification with similar or different fatty acids selected from the above-described fatty acids.

Moreover, as monoether astaxanthin can be taken monetary, esterified with amino acids such as glycine, alanine and the like; mono - or aminocarbonyl acids such as acetic acid, citric acid or the like; inorganic acids such as phosphoric acid, sulfuric acid, etc.; saccharides, such as glucoside or the like; with glikozidnuu acid, such as glycopyranoside acid is one or fingerlickin acid; with glycerophosphoric acid, etc. In the case of the salt above monoamino is enabled.

As diapir astaxanthin can be taken diesters, esterified with similar or different acids selected from the above-mentioned lower saturated fatty acids, higher saturated fatty acids, low in unsaturated fatty acids, higher unsaturated fatty acids, amino acids, mono - or polycarboxylic acids, inorganic acids, sugars, glikozidnuu acids, fatty acids and glycerophosphoric acid. In the case of the salt of the above diesters included. As diapir glycerophosphoric acid can be recovered ester of saturated fatty acid or glycerophosphoric acid or esters glycerophosphoric acid containing one of polyunsaturated fatty acids, unsaturated fatty acid and saturated fatty acid.

In order to increase the effect of astaxanthin and extract algae Haetmatococcus to reduce the content of fat in the body in the present invention, one or more active ingredients, adsorbents and solvents can be included in the astaxanthin or extract algae Haetmatococcus.

Examples of active ingredients include substances of vitamin a, carotenoids, substances of vitamin b substances With vitamin C, nutrients vitamins to anti scar is on D, substances of vitamin E, tocotrienol, glutathione, their derivatives and their salts: α-ribosylate, deoxyribonucleic acid, ribonucleic acid, adenosine triphosphate, adenosine monophosphate, glycerin, glitzirrizinovu acid, guanine, xanthine, α - or γ-linolenic acid, eykozapentaenovuyu acid, succinic acid, estradiol, their derivatives and their salts; aspartic acid, α-gidrokshikislotu, such as glycolic acid, lactic acid, malic acid, salicylic acid, etc. extract deproteinizing serum, spleen extract, placenta extract, extract scallops, king Jerry, extract yeast extract, lactic acid bacteria, extract of bifidobacteria,Fomes Japonioucusextract, extract of carrot,Swertiaextract, rosemary extract, philodendron black extract, garlic extract, hinokitiol, referentin, aloe extract,Salvia splendens,the Arnica extract, chamomile extract, white birch,hypericumextract,Eucalyptusextract,Xuan Fu Huaextract,patholobus suberectus Dunnextract, Sanpenzu extract, moricortex extract,Angericaextract,Bistortaextract,Sophoraextract,Crataegusextract, white Lily extract, extract of hops, extract of the white rose,Coix lacryma-jobiextract; D-fraction, glycogen, octacosanol, allicin, coenzyme Q10, catechin; cysteine, its derivatives and salts; peptides; l the zine, allilaire, Biotin, Pantothenic acid, collagen, elastin, keratin, their derivatives and their salts, hyaluronic acid, hondroitinsernaya acid, dermatooncology, hepatitis.what, heparin, keratinolytic; lactic acid bacteria; minerals such as iron, molybdenum, calcium, zinc, selenium, magnesium, copper, iodine, etc Tocopherol, tocotrienol, α-ribosylate, coenzyme Q10 and their derivatives are preferred.

As the adsorbent, which can be included in the composition to reduce the amount of fat in the body in the present invention, can be taken sugars, such as lactose, sucrose and the like, alcohols such as sorbitol, mannitol, xylitol and the like, inorganic compounds, such as alumosilicate magnesium, hydrotalcite, anhydride calcium phosphoric acid, calcium carbonate, anhydride salicylic acid, silicon dioxide, talc and the like, cellulose, starches, gelatin and agar.

The composition of the present invention can be obtained by wet or dry granulation of astaxanthin or extract algae Haetmatococcus and/or the active substance and the solvent. In wet granules it can be obtained by conventional methods, for example spray drying, granulation in the liquefied layer granulation by mixing or by freeze-drying.

As the solvent, the cat is who can be included in the composition to reduce the amount of fat in the body in the present invention, can be taken triglycerides medium chain fatty acids, edible fat and oil, esters of fatty acids, glycerol, ethylene glycol, etc. To obtain the compositions of the present invention astaxanthin or extract algae Haetmatococcus and /or active substance and the solvent can be mixed together in accordance with generally accepted way. The mixture is adsorbed on the above adsorbents and subjected to graining, thus, the composition of the present invention can be also obtained. The presence of these adsorbents and solvents effectively prevents oxidation of astaxanthin due to the fact that the contact area of astaxanthin with air becomes small. They are also effective for the protection of astaxanthin, as he passes on part of the digestive tract, such as the intestines, etc.

In the composition of the present invention astaxanthin contained in an amount of 0.001 to 99.9%, preferably from 0.01 to 20%, more preferably 0.1 to 10%, based on the total weight of the composition. In the composition of the present invention the extract of algae Haetmatococcus containing astaxanthin, is contained in a quantity of 0.001 to 99.9%, preferably 0.1 to 80%, more preferably 1-50% by weight of the total composition.

The composition contains 0.05 to 2 wt. parts, preferably 0.1 to 1 wt. parts of active ingredient, 1 to 1,000 wt. parts, p is edocfile 2-500 wt. parts of the adsorbent and 0.05-2 wt. part, preferably 0.1 to 1 wt. part of the solvent for 1 wt. part of astaxanthin. 1 wt. part of the extract algae Haetmatococcus containing astaxanthin, containing 0.01-1 wt. part, preferably 0.02 to 0.5. parts of active ingredient, 1 to 1,000 wt. parts, preferably 2-500 wt. parts of the adsorbent and 0.05-2 wt. part, preferably 0.1 to 1 wt. part of the solvent.

The number entered or accepted the present composition is 0.2-100 mg, preferably 0.5 to 20 mg free astaxanthin for adults per day. Is oral administration or parenteral administration. The amount of the composition may vary depending on age, body weight and severity of symptoms of patients who entered the composition and dosage forms.

The term "the effect of reducing the amount of fat in the body" means the effect of reducing the amount of fat in the body and normalize the amount of fat in the body, as well as warning of increasing the amount of fat in the body and its normalization increases, despite the absence of changes in body mass. Use light exercise periodically at that time, as the composition for reducing body fat in the present invention is introduced or adopted, may increase the effect of reducing the amount of fat in organisms is E. Through the introduction or admission of a composition to reduce the amount of body fat in the present invention increase the amount of fat in the body can be prevented and, therefore, the effect of preventing obesity.

Reducing excess body fat is a cause of effective treatment, improvement and prevention of diseases, which cause called obesity or excessive body weight, such as diabetes, atherosclerosis, essential hypertension, cancer, hyperlipidemia, rheumatism, hyperuricemia, deforming arthritis, gout, stroke, ischemic heart disease, lung disease, pancreatitis, cataracts, Alzheimer's disease, allergic disease, angina, edema, ischemic heart disease, complications of diabetes, polyneuropathy, and retinopathy.

With respect to damage to the nerves it is effective treatment, improvement and prevention of progressive deafness, vision impairment and paralysis of the face and pain, orthostatic hypotension, excessive sweating, diarrhea and constipation (diseases of the digestive tract), dysuria, diseases of the membranes, impaired trophic, sensitivity, muscle atrophy and ulcers. In relation to visual impairment it is effective in treating, improving, and before whom the prevention of cataracts, simple retinity, preproliferative retinopathy, proliferative retinopathy. Also relatively ischemic diseases it is effective in the treatment, the improvement and the prevention of heart attacks, brain and heart attacks heart.

As an exercise, increase the effect of reducing the amount of fat in the body, in the present invention can be applied exercise, such as walking, Cycling, climbing, aerobics, workout at the gym, water aerobics, swimming, etc. They can be used 2-4 times a week for 30 minutes - 2 hours.

The composition of the present invention can be formed into a drug in such forms as tablets, sublingual tablets, pills, suppositories, powder form, powder, fine granules, granules, capsules, micro-capsules, injectable solutions, emulsions, plasters and the like, for Example, tablets can be obtained by homogeneous mixing of the composition of the present invention with a pharmaceutically acceptable carrier and a mixture for the preparation of tablets. Can also be obtained crushed form, powder and granules by exposure of the composition of the present invention and medium dry granulation and wet granulation. The wet granules can be obtained by conventional methods, for example dissolved, and the extreme drying, granulation in the liquefied layer granulation by mixing or by freeze-drying. Can also be obtained chewing or broken tablets for ingestion through the conventional method depending on the need.

Mashed form, powder, fine granules, granules and tablets can be obtained by using excipients such as lactose, glucose, sucrose, mannitol, alumosilicate magnesium, synthetic hydrotalcite, anhydrous calcium phosphate and the like; disintegrators such as starch, sodium alginate or the like, lubricants such as magnesium stearate, talc or the like; a connecting means, such as polyvinyl alcohol, hydroxypropylcellulose, gelatin or the like; fillers, such as fatty acid esters or the like; plasticizers such as glycerin or the like

Composition comprising astaxanthin or its ester as an effective ingredient in the present invention can be appropriately combined with sugar alcohols such as sorbitol, mannitol, xylitol, aritra, ▫ maltitol, and the like; sugars such as lactose, sucrose, ▫ maltitol, and the like; and inorganic excipients such as alumosilicate magnesium, hydrotalcite, magaldrate, anhydrous calcium phosphate, calcium carbonate and the like; binders such as starch, gelatin, methylcellulose, poly is vinylpyrrolidone etc.; the disintegrators such as starch, agar, crosspovidone, crystalline cellulose and the like; lubricants, such as silica, talc, magnesium stearate, polyethylene glycol etc., taste enhancers and sweeteners, whereby can be obtained from various forms of medication, such as medication, administered in such dosage forms as solid preparations such as tablets disintegrated tablets for oral administration, capsules, granules, fine granules and the like, and in such dosage forms as liquid preparations such as elixirs, syrups and suspensions.

To reduce the decomposition and oxidation of astaxanthin or its ether the substance with antioxidant capacity, as a stabilizer, may be added to the above compositions, if necessary. For example, one, or two or more mixtures selected from such existing antioxidants like vitamin a, vitamin b, vitamin C and vitamin E or derivatives of these vitamins, tocotrienol, cysteine, glutathione, glutathione peroxidase, citric acid, phosphoric acid, polyphenols, nucleic acids, herbal medicines, algae, inorganic substances can be added to the above composition. They are suitable for incorporation into the final powder form in order to increase the absorption of free astax ntina or monoether.

If necessary, another antioxidant may be added to the compositions of the present invention. The antioxidant is unlimited. One of them may be used, if it has an antioxidant effect. You can select one, two or more antioxidants from the group comprising substances of vitamin a such as retinol, 3,4-dihydroxyethyl and the like; vitamin b; substances of vitamin C, such as D-ascorbic acid, L-ascorbic acid and the like; substances of vitamin E such as tocopherol, tocotrienol, acetate, vitamin E succinate vitamin E phosphate, vitamin E, co-enzyme, a flavonoid, tannin, slavikova acid, polyphenols, inhibitors of free radicals, which means that Deplete the hydroperoxides, the means of alkali metals, tools, remove active oxygen; carotenoids containing α-carotene, β-carotene, γ-carotene, δ-carotene; tachocline; their pharmacologically acceptable salts and mixtures thereof.

Injectable form can be produced in accordance with the conventional method and by mixing the effective ingredient with one or more tools selected from pH-regulating means, the buffer means, solvents, suspensions; tools that make the solution isotonic, stabilizers, antiseptics as needed.

Examples of suspensions include Polysorbate 80, methylcellulose is, hydroxyethyl cellulose, sodium carboxymethyl cellulose, polyoxyethylenesorbitan monolaurate, gum Arabic, powder tragakant etc. are Examples of solvents include Polysorbate 80, polyoxyethylene, hydrogenated waste oil, nicotinamide, polyoxyethylenesorbitan monolaurate, macrogol, ethylether waste oil fatty acids and the like, examples of the antiseptics include methylhydroxybenzoate, ethyl p-hydroxybenzoate, sorbic acid, phenol, cresol, chlorocresol etc.

The composition of the present invention medicines can be contained in an amount of 0.01 to 99.9% by weight, preferably 0.1 to 90% by weight. This is determined by adequate dependent on a daily dose.

The composition of the present invention can be used for cooking and drinking, has the effect of decreasing the amount of fat in the body.

As food and drink can be consumed healthy foods, such as functional food, food for special medical use and additional meals or shared food and drink.

As a General food and drink composition of the present invention can be used, for example, in addition to common foods and drinks, such as margarine, butter, butter sauce, cheese, raw cream, baking powder dough, lard, ice cream, yoghurt, dairy products, meat products,fish products, to fried potatoes, potato chips, popcorn, chewing gum, chocolate, pudding, jelly, chewing candy, candy, candy, candy, the spongy muffins, peronema, doughnuts, biscuits, crackers, etc., pasta, pasta, butter lettuce, instant soups, eggs, mayonnaise,misoetc. or carbonated or non-carbonated drinks such as fruit drinks, soft drinks, sports drinks, etc. and non-alcoholic drinks such as tea, coffee, cocoa, etc., or alcoholic beverages such as liquors, liqueurs, etc.

When food or drink of the present invention is used as a healing power, such as functional food, food for special medical use and more power so that its shape can be similar to the form described above drugs. Can be also used milk protein, soy protein, egg protein, etc. or their component substances such as oligopeptides albumin, soy hydrolysate, a mixture of amino acids. Food can also be presented in the form of natural liquid products, semi-finished products and food, beverages, capsules or enteral nutrients, etc. mixed with sugars, fats, trace elements, vitamins, emulsions, flavors, etc. as drinking forms taken such substances that can in order to mesyatsa drinking, as dietary supplements, such as amino acids, vitamins, minerals, etc. and sweeteners, spices, flavor enhancers, pigments, etc., they are added to maintain the balance of nutrients or give a good taste.

In the case where the composition of the present invention is introduced into food and drink, this is done with the raw materials of the most common food and drink in the usual ways. The number added to the compositions of the present invention is not so limited and may vary in food. It may be generally within 0.00001 to 10% by weight, preferably within 0.00001-5% weight and adjustable to the required number for the manifestation of the effect of reducing the amount of fat in the body. The number used may be selected depending on the type of food and drink. Despite the fact that the number of compositions of the present invention may vary depending on the type of food, in General it is described as the amount of free astaxanthin about 0.2-100 mg, preferably 0.5 to 20 mg per day for adults.

In the case where the food of the present invention is used as nutritional support or functional food, forms may be similar to the above drugs. Form of food in the present invention is not limited to them. Also in order to reduce the amount of fat in the animal body, the composition of the present invention may apotre is given them as food.

The present invention is illustrated in more detail by the following examples, but we cannot say that the present invention be limited by them.

Obtaining an extract of seaweed Haetmatococcus

80 kg and dried unground powder seaweed Haetmatococcus (product Asta Real AV Company, the content of astaxanthin 3.7%) and 2 kg of a mixture of vitamins (product of Riken Vitamin, e) were dispersed in 120 kg of acetone and the product dispersion was subjected to a double-grinding using antiwrinkle type bubble crusher (DYDO-MILL KDL-25BC, product WAB Company), in which the bubbles having a diameter of 1 mm were compressed prior to occupancy to 85% at room temperature, cooled if necessary, when using a disk peripheral speed of 10 m/s and flow rate 100 kg/h extraction of the lipid fraction containing carotenoids.

The total number squeezed suspension was subjected to filtration with the return of the filtrate. Moreover, the residue of the filtrate was washed three times with 40 kg of acetone for full extraction of the lipid ingredients containing carotenoids. The total number of received extracted filtrate was concentrated under reduced pressure (100 Torr, 45°C) for the return of acetone and extract algae Haetmatococcus containing 5.0% of astaxanthin in the form of the free form. Algae Haetmatococcus used C the ect, was cultivated using hermetic type cultivation device.

Extract algae Haetmatococcus was enclosed in capsules containing 6 mg of astaxanthin in the form of the free form (test capsule) and tested. Placebo capsule (placebo capsule)containing 0 mg of astaxanthin and having a similar appearance, was used in the test.

32 people were studied, they were healthy women 23-57 years, they were divided at random into 2 groups, i.e. on the study and control groups, each of which was 16 people. Accommodation analyzed in the study and control group was conducted double-blind - unknown, who investigated and actually participate in the study.

Each of the people studied in the test group received two test capsules per day after dinner, while each of the people in the control group received two placebo capsules per day after dinner. The study period (test period) was 6 weeks. Assessment of fat content in the body and the body weight was conducted at the beginning (0 weeks) and finally (6 weeks) studies all investigated. Evaluation the amount of fat in the body was carried out by using weights (TBF-511 production Tanita Go. Ltd.)

Load exercises in this test period

Physical activity in all investigated in the study period were about wlci. The amount of exercise was determined by the maximum number of heartbeats counted electronically.

The walk lasted 40 minutes before reaching 60-70% of the maximum number of heartbeats in people having the maximum oxygen intake of more than 40 ml/kg/min until reaching 50-60% of the maximum number of heartbeats in people having the maximum oxygen below 40 ml/kg/min Walks were conducted 3 times a week.

Table 1
The change in the average amount of body fat(%)
Before the testAfter the testThe change in the average amount of body fat(%)
The test group27,6±3,226,6±2,9-3,6
The control group26,6±3,126,8±3,60,8

A: p>0,05 (t-test, the control group compared with the test group)

/tr>
Table 2
The change in mean body weight (kg)
Before the testAfter the testThe change in the average amount of body fat(%).
The test group55,7±5,455,5±5,1-0,4
The control group54,1±6,354,4±6,30,6

A: p>0,05 (t-test, the control group compared with the test group)

Table 1 shows the average fat content in the body and table 2 shows the change in mean body weight. Found no significant changes in body weight in both groups. The estimated fat content in the body in the study group, modified from 27.6% to 26.6 per cent, shows that the fat content in the body is decreased by 3.6%. In contrast, the estimated fat content in the body in the control group changed only from 26.6% to 26.8%, shows that there are noticeable differences.

Identified by this result that the estimated fat content in the body is reduced due to the use of astaxanthin.

Example of getting 1. Tablet

The following ingredients were homogeneous mixed together in the composition ratio and the powder dry. Then the final powder is OK was molded into tablets, which contain 300 mg of astaxanthin.

Extract algae Haetmatococcus 300 mg

Lactose 70 mg

Starch 70 mg

Sodium Caseinate 6 mg

Gelatin 6 mg

Cellulose 109 mg

Silicon dioxide 3 mg

Fatty acid ester of sucrose 6 mg

Extract algae Haetmatococcus contains 5 wt.% astaxanthin in a free form.

Example of getting a 2. Soft capsule

Extract algae Haetmatococcus (the content of astaxanthin 5 wt.%) was mixed with an edible oil and fat included in the outer shell of the capsules containing the following ingredients, in accordance with the generally known method of manufacturing soft capsules, the weight of which was 300 mg.

Internal filling

Extract algae Haetmatococcus 20 mg

Edible oil and fat 150 mg

The outer casing

Gelatin 100 mg

Glycerin 30 mg

The following ingredients were mixed together and 10 kg of water was added in accordance with generally accepted method of preparation of the drink.

Example of getting a 3. Drink

Aqueous extract of algae Haetmatococcus* 25 g

Liquid sugar 4000 g

Citric acid 1 g

Vitamin C 50 g

Vitamin E 50 g

Cyclodextrin 150 g

Potassium chloride 25 g

Magnesium sulfate 5 g

*Aqueous extract of algae Haetmatococcus (the content of astaxanthin 1%) get method, for example, described in JP 2001-316601 A.

Example 4. L is pKa pellet

The following ingredients were mixed and crushed in accordance with generally accepted way of getting sticky granules, each of which contains 5,

Powder astaxanthin 5%

The mixture of b vitamins 1%

Nicotinic acid 0,1%

Pantothenic acid 0,1%

Taurine 10%

Glutamic acid 1%

GABA 0,01%

Aspartic acid 0,5%

BCAA 10%

Citric acid 10%

Vitamin C 10%

γ-oryzanol powder 0,15%

The N balance

Dextrin balance

*Powder extract, algae Haetmatococcus (the content of astaxanthin 1 wt.%).

1. Composition for reducing the amount of fat in the body, containing astaxanthin as an effective ingredient, in a quantity from 0.001 to 99.9% by weight of the total composition.

2. The composition according to claim 1, in which the content of astaxanthin is from 0.01 to 20.0% by weight of the total composition.

3. The composition according to claim 1, in which the content of astaxanthin is from 0.01 to 10.0% by weight of the total composition.

4. Composition for reducing the amount of fat in the body, which is obtained by grinding the Haematococcus algae and extraction of crushed algae Haematococcus solvent, in which the extract of the Alga Haematococcus containing astaxanthin, is contained in a quantity of 0.001 to 99.9% by weight of the total composition.

5. The composition according to claim 4, in which the extract of the Alga Haematococcus, with the holding astaxanthin, is contained in an amount of 0.1-80.0% in the calculation of the total mass of the composition.

6. The composition according to claim 4, in which the extract of the Alga Haematococcus containing astaxanthin contained in the amount of from 1.0 to 50.0% by weight of the total composition.

7. Composition according to any one of claims 1 to 3, which includes the entered one or more active ingredients, the adsorbent and the solvent, and the composition comprises from 0.05 to 2.0 parts by weight of active ingredient, 1 to 1,000 parts by weight of the adsorbent and 0.05 to 2.0 parts by weight of solvent to 1 parts by weight of astaxanthin.

8. The composition according to claim 7, which comprises 0.1 to 1.0 parts by weight of active ingredient, 2-500 parts by weight of the adsorbent and 0.1 to 1.0 parts by weight of solvent to 1 parts by weight of astaxanthin.

9. The means for lowering the body fat, which contains any of the compositions defined in claims 1 to 8.

10. Food and drink to reduce fat in the body that include any of the compositions defined in claims 1 to 8.

11. The way to reduce fat in the body, which includes the introduction or admission by any person of a composition according to claims 1 to 8 in the amount of 0.2-100.0 mg per day in terms of free astaxanthin.

12. The method according to claim 11, which includes the introduction or admission of a person of 0.5-20.0 mg per day of the composition in terms of free astaxanthin.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cosmetology and can be used for skin care. For this purpose, artesian water synthetically enriched with active oxygen forms is used. It is applied on face or body skin by means of a guided pulveriser-sprayer.

EFFECT: method provides minimum duration of application of irrigation procedure, enables the permanent intended use regardless of time and a place.

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary. The preparation contains the following drugs: L-arginine monohydrochloride in amount 48-72 mg/l, L-lysine monohydrochloride in amount 48-72 mg/l, L-histidine monohydrochloride in amount 13.8-20.8 mg/l, L-isoleucine in amount 13.8-20.8 mg/l, L-leucine in amount 41.6-62.4 mg/l, L-methionine in amount 10.4-15.6 mg/l, L-phenylalanine in amount 17.2-25.8 mg/l, L-threonine in amount 20.8-31.2 mg/l, L-tryptophan in amount 7.9-10.3 mg/l, L-glutamine in amount 68.8-103.2 mg/l, L-valine in amount 17.2-25.8 mg/l, L-tyrosine in amount 27.7-41.5 mg/l, L-cystine monochloride in amount 17.9-26.9 mg/l, L-serine in amount 17.2-25.8 mg/l, glycine in amount 34.4-54.6 mg/l, L-alpha-alanine in amount 17.2-25.8 mg/l, L-proline in amount 25.6-38.4 mg/l, L-aspartic acid in amount 18.0-30.0 mg/l, L-oxyproline in amount 7.9-10.3 mg/l, L-glutamic acid in amount 48-72 mg/l, L-cysteine monohydrochloride in amount 0.12-0.70 mg/l, choline chloride in amount 0.4-3.0 mg/l, folic acid in amount 0.01-0.09 mg/l, calcium pantothenate in amount 0.01-0.09 mg/l, thiamine hydrochloride in amount 0.01-0.09 mg/l, nicotinic acid in amount 0.03-0.22 mg/l, pyridoxal monohydrochloride in amount 0.03-0.22 mg/l, riboflavin in amount 0.012-0.09 mg/l, nicotinamide in amount 0.03-0.22 mg/l, D-biotin in amount 0.01-0.09 mg/l, myoinositol in amount 0.06-0.45 mg/l, pyridoxine hydrochloride in amount 0.03-0.22 mg/l, calciferol in amount 0.01-0.09 mg/l, ascorbic acid in amount 0.06-0.45 mg/l, p-amino-benzoic acid in amount 0.06-0.45 mg/l, glucose in amount 800-1200 mg/l, and the following inorganic salts: sodium chloride in amount 7.2-8.8 g/l, potassium chloride in amount 360-440 mg/l, one-substituted potassium phosphate in amount 54-66 mg/l, two-substituted 12-aqueous sodium phosphate in amount 13.5-16.5 mg/l, 6-aqueous calcium chloride in amount 24.8-30.4 mg/l, 6-aqueous magnesium chloride in amount 9.9-11.6 mg/l, 7-aqueous magnesium sulphate in amount 9.0-11.0 mg/l, 9-aqueous ferrous nitrate in amount 0.65-0.79 mg/l, 3-aqueous sodium acetate in amount 7.1-8.7 mg/l. The method for prevention and correction of diseased conditions in animals consists in the injection introduction in an animal of said preparation in the form of an aqueous solution for prevention 2 times a week for a month in dosage 1.5-2.0 ml per 10 kg of body weight, for therapy in dosage 3.0-5.0 ml per 10 kg of body weight 2 times a day for 3-5 days, at synthetic and/or food poisoning intoxications - in a tenfold therapeutic dose. And, if a dose of the preparation exceeds 20 ml, it is injected in more points.

EFFECT: invention provides higher therapeutic and preventive effectiveness.

6 cl, 8 tbl

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention relates to immunology and biotechnology. The invention discloses versions of a cytotoxically active CD3-specific binding structure. The structure comprises a first domain specifically binding to human CD3 and an Ig-derived second binding domain which is specific to molecules on the cell surface. The invention describes a coding nucleic acid, a vector for expressing the structure and an eukaryotic cell transformed by the vector. The invention discloses versions of compositions based on the structure for treating, preventing or alleviating various diseases and corresponding methods of treating the diseases. A method of obtaining the structure is disclosed.

EFFECT: use of the invention provides a structure with low immunological potency, which has cytotoxicity comparable to the initial structure, which may find further use in medicine.

60 cl, 18 dwg, 15 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of purifying plant extracts which mainly consist of noroxymorphone compounds and contain α,β-unsaturated noroxymorphone compounds as impurities, through (a) conversion of a plant extract or product of the next step in synthesis of the selected noroxymorphone compound as a result of conversion of hydroxyl groups present in the mixture to groups of formula -OR2 which can be split, in which R2 is an introduced radical of the said group which can be split, (b) said groups, if necessary, can be removed once more, after which (c) the obtained mixture is subjected to selective hydrogenation so that a saturated bond forms in the α,β-position of unsaturated noroxymorphone compounds and all the remaining groups which can be split are converted to a hydroxyl group, after which (d) a pure noroxymorphone compound is extracted; processing the purified noroxymorphone to naltrexone or naloxone or a salt of these compounds or a quaternary derivative of these compounds, which are known pharmaceutically active compounds particularly used for reducing psychological dependency and during drug abuse.

EFFECT: improved purification of compounds.

21 cl, 8 ex

FIELD: medicine.

SUBSTANCE: lytic exoenzyme of Cellulomonas cellulans strain RNCIM AS-870 of molecular weight within 100 to 30 kDa and specific activity 48.3 UN/mg of protein and more is used. A preparation for treating mycotic infections contains lytic exoenzyme of Cellulomonas cellulans strain RNCIM AS-870 of molecular weight within 100 to 30 kDa and specific activity 48.3 UN/mg and more of protein and represents a topical drug.

EFFECT: lower probability of recurrences in treating mycotic infections without normal flora suppression.

10 cl, 4 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: for correction of endothelial dysfunction in experiment on rats dysfunction is modelled by preliminary sensitisation of animal with staphylococcus anatoxin in doze 0.1 ml subcutaneously. Then after 24 hours in the same place as anatoxin introduced is suspension of Staphylococcus aureus subcutaneously in dose 60 billions of microbial bodies in 1 ml. After that for following generalisation of infectious agent, daily massage of injection place is carried out. At this background introduced is macrolidal medication azithromycin intragastrically in dose 30 mg/kg/day.

EFFECT: method ensures activation of endothelial dysfunction correction.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: in order to estimate resorbtion function of peritoneum time during which animals achieve stage of surgical sleep in case of intraperitoneal introduction of ethaminal is determined.

EFFECT: method allows to estimate indirectly resoptive function of peritoneum in norm and under impact of aggressive factors.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery. Solution of dye is introduced in proper segmental vessel by direct injection method. Preliminarily, before introduction of dye solution, feeding artery is compressed for 2-3 minutes, dye solution is introduced more distally than compression place and after 1-2 minutes respective vein is compressed. Simultaneously area of supposed staining is influenced by source of constant magnet, placed outside of the organ surface.

EFFECT: method extends arsenal of means for marking intraorgan zones, segments of parenchymatous organs.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to experimental medicine and deals with restoration of reducing with age potential of cell growth of tissues in old laboratory animals. For this purpose medication "Transfer-factor" is introduced to laboratory animals in dose corresponding to 1 capsule a day per 50 kg of weight.

EFFECT: method ensures activation of T-lymphocyte function and restoration of potential of cell growth of salivary gland tissues in said group of animals.

FIELD: medicine.

SUBSTANCE: invention relates to chemical and pharmaceutical industry, namely to creation of medication reducing hematotoxicity of cytostatics. As such medication, polysaccharides from leaves of coltsfoot (Tussilago farfara L.) are used.

EFFECT: medication extends arsenal of preparations increasing efficiency of chemical therapy by reducing henatotoxicity of cytostatics.

2 tbl

Feet care product // 2402314

FIELD: medicine.

SUBSTANCE: invention refers to cosmetology, particularly to a feet care product. The feet care product contains an oil phase, an inorganic excipient, hexamethylene tetramine, a cosmetically acceptable solid base and essences taken in a certain ratio.

EFFECT: product is effective for feet care, exhibits improved hidroschesis.

6 cl, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to ophthalmology and can be used in treating the patients suffering actinomycosis of lachrymal passages. That is ensured by irrigation of lachrymal ducts with Actinolysatum in amount 3 ml 3 times a week, total 10 irrigations. Besides Actinolysatum is injected intramuscularly in a single dose, 2 injections a week, total 10 injections.

EFFECT: method provides higher clinical effectiveness of conservative modalities in the given pathology without a surgical intervention due to combination of a certain local effect Actinolysatum on ray fungi and its systemic action.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dentistry and can be used for treatment and prevention of dental caries and gingivitis. For this purpose cotton tampons, soaked with medicinal oil, are applied on gum parts and changed tooth enamel for 20 minutes 2-3 times per day. Oil is prepared by infusion of 1 part of vegetable raw material on 5 parts of olive oil at t 85°-90° for 5 hours. Ratio of raw material components constitutes, wt, pt.: rhizomes and roots of great burnet - 1.0; flowers of pot marigold - 1.0; cloves buds - 0.2. Into obtained oil 1 ml of 0.02% of ecdysterone in ethyl alcohol is added.

EFFECT: method ensures high degree of affected tissue regeneration, good bactericidal and anesthetic action, reduction and complete termination of gum bleeding, elimination of hyperemia and edema, disappearance of chalk-like enamel spots with absence of any negative impacts on tissues of teeth and periodontium.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dentistry and can be used for treatment and prevention of dental caries and gingivitis. For this purpose cotton tampons, soaked with medicinal oil, are applied on gum parts and changed tooth enamel for 20 minutes 2-3 times per day. Oil is prepared by infusion of 1 part of vegetable raw material on 5 parts of olive oil at t 85°-90° for 5 hours. Ratio of raw material components constitutes, wt, pt.: rhizomes and roots of great burnet - 1.0; flowers of pot marigold - 1.0; cloves buds - 0.2. Into obtained oil 1 ml of 0.02% of ecdysterone in ethyl alcohol is added.

EFFECT: method ensures high degree of affected tissue regeneration, good bactericidal and anesthetic action, reduction and complete termination of gum bleeding, elimination of hyperemia and edema, disappearance of chalk-like enamel spots with absence of any negative impacts on tissues of teeth and periodontium.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dentistry and can be used for treatment and prevention of dental caries and gingivitis. For this purpose cotton tampons, soaked with medicinal oil, are applied on gum parts and changed tooth enamel for 20 minutes 2-3 times per day. Oil is prepared by infusion of 1 part of vegetable raw material on 5 parts of olive oil at t 85°-90° for 5 hours. Ratio of raw material components constitutes, wt, pt.: rhizomes and roots of great burnet - 1.0; flowers of pot marigold - 1.0; cloves buds - 0.2. Into obtained oil 1 ml of 0.02% of ecdysterone in ethyl alcohol is added.

EFFECT: method ensures high degree of affected tissue regeneration, good bactericidal and anesthetic action, reduction and complete termination of gum bleeding, elimination of hyperemia and edema, disappearance of chalk-like enamel spots with absence of any negative impacts on tissues of teeth and periodontium.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dentistry and can be used for treatment and prevention of dental caries and gingivitis. For this purpose cotton tampons, soaked with medicinal oil, are applied on gum parts and changed tooth enamel for 20 minutes 2-3 times per day. Oil is prepared by infusion of 1 part of vegetable raw material on 5 parts of olive oil at t 85°-90° for 5 hours. Ratio of raw material components constitutes, wt, pt.: rhizomes and roots of great burnet - 1.0; flowers of pot marigold - 1.0; cloves buds - 0.2. Into obtained oil 1 ml of 0.02% of ecdysterone in ethyl alcohol is added.

EFFECT: method ensures high degree of affected tissue regeneration, good bactericidal and anesthetic action, reduction and complete termination of gum bleeding, elimination of hyperemia and edema, disappearance of chalk-like enamel spots with absence of any negative impacts on tissues of teeth and periodontium.

3 ex

FIELD: chemistry.

SUBSTANCE: Chinese magnolia is extracted with liquefied carbon dioxide. The obtained CO2 extract undergoes chromatographic separation on aluminium oxide and eluated with hexane. After eluation the obtained hexane fractions are frozen and recrystallised from the chloroform-hexane mixture in ratio of 1:10-3:10.

EFFECT: high output of product.

1 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for treating syphilis and viral diseases specified from influenza, human immunodeficiency virus, cytomegalovirus infections, viral hepatitis type A, D, C and herpes infections, containing an amount of polyphenol compounds of sea buckthorn leaves, including at least 60 % of halloellagotannines, flacoside, a pharmacologically acceptable carrier and a substance of licorice extract, or glycyrrhizic acid, or its pharmaceutically acceptable salt, acridonoacetic acid or its pharmaceutically acceptable salt, birch bark extract or betulin taken in therapeutically effective amounts. A method of treating syphilis and viral diseases, including the introduction of the declared pharmaceutical composition by 2-3 doses 3 times a day.

EFFECT: composition exhibits an evident antiviral action with respect to the infections stated above.

22 cl, 1 dwg, 12 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for treating syphilis and viral diseases specified from influenza, human immunodeficiency virus, cytomegalovirus infections, viral hepatitis type A, D, C and herpes infections, containing an amount of polyphenol compounds of sea buckthorn leaves, including at least 60 % of halloellagotannines, flacoside, a pharmacologically acceptable carrier and a substance of licorice extract, or glycyrrhizic acid, or its pharmaceutically acceptable salt, acridonoacetic acid or its pharmaceutically acceptable salt, birch bark extract or betulin taken in therapeutically effective amounts. A method of treating syphilis and viral diseases, including the introduction of the declared pharmaceutical composition by 2-3 doses 3 times a day.

EFFECT: composition exhibits an evident antiviral action with respect to the infections stated above.

22 cl, 1 dwg, 12 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition for treating syphilis and viral diseases specified from influenza, human immunodeficiency virus, cytomegalovirus infections, viral hepatitis type A, D, C and herpes infections, containing an amount of polyphenol compounds of sea buckthorn leaves, including at least 60 % of halloellagotannines, flacoside, a pharmacologically acceptable carrier and a substance of licorice extract, or glycyrrhizic acid, or its pharmaceutically acceptable salt, acridonoacetic acid or its pharmaceutically acceptable salt, birch bark extract or betulin taken in therapeutically effective amounts. A method of treating syphilis and viral diseases, including the introduction of the declared pharmaceutical composition by 2-3 doses 3 times a day.

EFFECT: composition exhibits an evident antiviral action with respect to the infections stated above.

22 cl, 1 dwg, 12 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to salts of valnemulin compounds of formula I and organic acids selected from a group which includes D-tartaric acid and fumaric acid, (I). The invention also relates to method for synthesis of said salts and to their use as a medicinal agent for treating bacterial infections in warm-blooded animals.

EFFECT: obtaining novel salts of valnemulin which are characterised by high degree of crystallinity and high degree of purification, manufacturability and high stability during storage.

14 cl, 1 tbl, 3 ex

Up!